Li Zhang

Dr. Li Zhang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
XMXiaoyu Ma
Xiaoyu Ma
ZXZengmai Xie
Zengmai Xie
HWHuan Wang
Huan Wang
ZTZhongping Tian
Zhongping Tian
Yanlong BiYanlong Bi
Yanlong Bi
LZLi Zhang
Li Zhang
Background: The involvement of retina and its vasculature has been recently described in Alzheimer’s disease (AD). Optical coherence tomography angiography (OCTA) is noninvasively used to assess the retinal blood flow.Objective: This study was to compare vessel density (VD) and blood perfusion density (PD) of the macular in AD patients, mild cognitive impairment (MCI) patients and healthy controls by OCTA, which may provide new ideas for diagnosis of AD or MCI.Methods: AD patients, MCI patients and healthy controls underwent a comprehensive ophthalmic and neurological evaluations, including cognitive function assessments as well as visual acuity, intraocular pressure (IOP), slit lamp examinations, and OCTA. General demographic data, cognitive function, retinal VD and PD were compared among three groups. The correlations among retinal VD, PD and cognitive function, amyloid-beta (Aβ) protein and phosphorylated Tau (p-Tau) protein were further evaluated. The correlations between retinal superficial capillary plexus and cognitive function, Aβ protein and p-Tau protein were also explored.Results: A total of 139 participants were recruited into this study, including 43 AD patients, 62 MCI patients, and 34 healthy controls. After adjusting for sex, age, history of smoking, history of alcohol intake, hypertension, hyperlipidemia, best corrected visual acuity, and IOP, VD and PD in the nasal and inferior regions of the inner ring, superior and inferior regions of outer ring in the AD group were significantly lower than in the control group (p < 0.05). PD in nasal region of outer ring also significantly decreased in the AD group. VD and PD in superior and inferior regions of inner ring, superior and temporal regions of outer ring in the MCI group were markedly lower than in the control group (p < 0.05). After adjusting for sex and age, VD and PD were correlated with Montreal Cognitive Assessment Basic score, Mini-mental State Examination score, visuospatial function and executive function (p < 0.05), while Aβ protein and p-Tau protein had no relationship with VD and PD.Conclusion: Our findings suggest that superficial retinal VD and PD in macula may be potential non-invasive biomarkers for AD and MCI, and these vascular parameters correlate with cognitive function.

31 May 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
JFJian Fan
Jian Fan
YYYi Yang
Yi Yang
JQJi-Kui Qian
Ji-Kui Qian
XZXin Zhang
Xin Zhang
JJJia-Qing Ji
Jia-Qing Ji
FYFeng Yuan
Feng Yuan
Osteosarcoma is a major malignant tumor of bone and soft tissue, which is presenting with early metastasis and a high mortality rate. Platelet activating factor acetylhydrolase 1B3 (PAFAH1B3), a cancer-relevant molecular, was found to play a vital role in tumorigenesis and aggressiveness in several cancer types. However, the roles and the regulating mechanisms of PAFAH1B3 in osteosarcoma progression remain unclear. PAFAH1B3 expression was detected by immunohistochemistry in 83 osteosarcoma tissues and 44 paired adjacent normal bone tissues. In vitro, loss-of-function assay was performed to explore the role of PAFAH1B3 in osteosarcoma cells. Tumor xenograft growth assay was used to verify the effect of PAFAH1B3 knockdown on osteosarcoma growth in vivo. Chip assay was carried out to investigate the mechanism in osteosarcoma proliferation regulated by PAFAH1B3. PAFAH1B3 was overexpressed in osteosarcoma tissues and cell lines. Moreover, PAFAH1B3 knockdown inhibited osteosarcoma cell proliferation and promoted apoptosis in vitro, and also suppressed osteosarcoma growth in vivo. Furthermore, the proliferative effect of PAFAH1B3 in osteosarcoma was related to the regulation of the expression of EIF4EBP1, MYC, PTGS2 and RPS6KB1. This study demonstrated the biological function of PAFAH1B3 on osteosarcoma proliferation. This research suggested that PAFAH1B3 could be a novel therapeutic target for osteosarcoma patients.

12 November 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
HWHuan Wang
Huan Wang
JZJiaqi Zheng
Jiaqi Zheng
QZQing Zhang
Qing Zhang
ZTZhongping Tian
Zhongping Tian
YSYuhang Sun
Yuhang Sun
LZLi Zhang
Li Zhang
Importance: Clinical trials in recent years have shown significant effectiveness of complement inhibitors for geographic atrophy (GA) treatment. Two complement inhibitor drugs have been approved by the Food and Drug Administration (FDA).Objective: to compare and rank the different complement inhibitors in the treatment of GA secondary to age-related macular degeneration (AMD).Data sources: A systematic literature search was conducted in the Cochrane Central, Web of Science Core Collection, PubMed, LWW Medical Journals, ClinicalTrials.gov, and WHO ICTRP from inception to October 2023.Study selection: All randomized clinical trials evaluating the effectiveness of complement inhibitors in patients diagnosed with secondary GA in AMD were identified.Data extraction and synthesis: This study followed Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) network meta-analysis Checklist of Items and the Cochrane Risk of Bias Assessment Tool for assessing the study quality. Multiple authors independently coded all titles and abstracts, reviewed full-text articles against the inclusion and exclusion criteria, and resolved all discrepancies by consensus. Random-effects network meta-analyses were applied. Bayesian network meta-analysis was performed using the BUGSnet package in R (4.2.0).Main outcomes and measures: The primary efficacy outcome was the change in GA lesion size (mm2) from baseline to month 12. The secondary efficacy outcome was the mean change in best-corrected visual acuity (BCVA) from baseline to month 12. Safety outcome measures included the number of subjects with serious adverse events (SAEs) and macular neovascularization (MNV).Results: Ten randomized controlled trials including 4,405 participants and five complement inhibitors were identified. Comparison with sham and SUCRA analysis showed that avacincaptad pegol 2 mg (MD: −0.58, 95% CrI: −0.97 to −0.18, SUCRA: 93.55), pegcetacoplan monthly (MD: −0.38, 95% CrI: −0.57 to −0.20, SUCRA: 81.37), and pegcetacoplan every other month (MD: −0.30, 95% CrI: −0.49 to −0.11, SUCRA: 70.16) have significant changes in GA lesion reduction. No treatments showed significant changes in BCVA and SAE compared with sham. Pegcetacoplan monthly (OR: 4.30, 95% CrI: 1.48–16.72) increased the risk of MNV. Avacincaptad pegol 2 mg demonstrated favorable outcomes in terms of SAE and MNV.Conclusion and relevance: Avacincaptad pegol 2 mg is the most effective complement inhibitor with better safety for the treatment of GA secondary to AMD.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022351515, Identifier PROSPERO CRD42022351515.

17 July 2025 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
PDF file
ZTZhongping Tian
Zhongping Tian
YGYinning Guo
Yinning Guo
XCXi Chen
Xi Chen
QZQifeng Zhou
Qifeng Zhou
YLYuan Liu
Yuan Liu
LZLi Zhang
Li Zhang
Purpose: To conduct a systematic comparative analysis of macular retinal thickness, retinal nerve fiber layer (RNFL) thickness, and ganglion cell-inner plexiform layer (GCIPL) thickness measurements between spectral-domain optical coherence tomography (SD-OCT) and swept-source OCT (SS-OCT) in healthy individuals, while establishing standardized cross-platform conversion algorithms through machine learning methodologies.Methods: In this cross-sectional investigation, 48 healthy adults (96 eyes) underwent macular retinal thickness assessment (ETDRS grid sectors), RNFL analysis (quadrant sectors), and GCIPL evaluation (six-sector annular divisions) using both SD-OCT (Cirrus HD-OCT 5000) and SS-OCT (Triton DRI-OCT). Inter-device measurement differences were evaluated through paired t-tests. Agreement metrics were quantified via intraclass correlation coefficients (ICCs) and Bland-Altman analysis. Four predictive models—linear regression (LR), LASSO regression, random forest regression (RF), and support vector regression (SVR)—were developed to estimate Triton DRI-OCT measurements from Cirrus HD-OCT 5000 outputs. Model efficacy was assessed using coefficient of determination (R2) and root mean square error (RMSE).Results: Statistically significant inter-device discrepancies (P < 0.001) were identified in 9 macular sectors, all GCIPL parameters (average and six-sector measurements), and RNFL measurements (average thickness and three quadrants, excluding nasal sector). ICC values demonstrated moderate-to-strong agreement: macular thickness (0.771–0.906), GCIPL (0.554–0.710), and RNFL (0.451–0.852). Machine learning models exhibited superior performance in central subfield thickness (CST) prediction, achieving test set R2 values of 0.930 (LR), 0.926 (LASSO), 0.936 (SVR), and 0.892 (RF). Linear regression maintained consistent predictive accuracy across parameters: CST (R2 = 0.930), RNFL (R2 = 0.845), and GCIPL (R2 = 0.760).Conclusion: Substantial measurement discrepancies preclude direct interchangeability of SD-OCT and SS-OCT datasets. Machine learning-derived conversion algorithms significantly improve cross-device comparability, offering a robust standardization framework for multicenter research and longitudinal data integration. This methodological advancement enables harmonized analysis of OCT metrics across heterogeneous imaging platforms.

10 April 2025 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
JSJiaqi Shen
Jiaqi Shen
XLXin Liu
Xin Liu
MLMingyue Lin
Mingyue Lin
YSYuting Shao
Yuting Shao
GNGuozhen Niu
Guozhen Niu
Yanlong BiYanlong Bi
Yanlong Bi
Purpose: This study aimed to assess corneal endothelial cell loss (ECL) following phacoemulsification and intraocular lens implantation (Phaco+IOL) in eyes with acute primary angle-closure glaucoma (APACG) and cataracts under different preoperative intraocular pressure (IOP) levels.Methods: This non-randomized controlled trial included 75 eyes from 75 patients with APACG and cataracts who underwent Phaco+IOL. All patients received pharmacotherapy and anterior chamber paracentesis before surgery and were grouped according to their preoperative IOP: the high-IOP group (IOP ≥ 25 mmHg) and the IOP-controlled group (IOP < 25 mmHg). IOP, visual outcome, endothelial cell density (ECD), hexagonality (HEX), coefficient of variation (CV), and central corneal thickness (CCT) were evaluated up to 3 months postoperatively. Baseline ECD, HEX, and CV parameters were measured in the contralateral eyes of all patients as a reference and compared with the postoperative results.Results: The average IOP decreased from 43.2 ± 4.8 mmHg to 16.5 ± 5.8 mmHg (p < 0.001) in the high-IOP group and from 18.3 ± 4.3 mmHg to 14.3 ± 3.2 mmHg (p < 0.001) in the IOP-controlled group on the first postoperative day. The changes in IOP were more significant in the high-IOP group (p < 0.001). The ECD at 3 months was 1705.2 ± 503.8 cells/mm2 in the high-IOP group and 2091.8 ± 330.1 cells/mm2 in the IOP-controlled group (p < 0.001). The ECL rates at 3 months were 35.0% (high-IOP group) and 17.4% (IOP-controlled group) (p < 0.001). The postoperative changes in HEX and CV at 3 months were more significant in the high-IOP group (p < 0.001; p = 0.003). Both groups produced comparable improvements in visual acuity and IOP.Conclusion: Uncontrolled high IOP (≥ 25 mmHg) before Phaco+IOL in patients with APACG and cataracts is associated with a higher rate of ECL. The rapid and substantial reduction of IOP during surgery may exacerbate corneal endothelial cell loss.Clinical trial registration: ClinicalTrails.gov, identifier ChiCTR2100052096.

12 January 2023 in Frontiers in Medicine
Verified
Journal Article
Open access
CLChunyu Liu
Chunyu Liu
XHXinyu Huang
Xinyu Huang
JSJiaqi Shen
Jiaqi Shen
YZYushan Zhang
Yushan Zhang
LZLi Zhang
Li Zhang
Yanlong BiYanlong Bi
Yanlong Bi
Purpose: To evaluate the clinical effects of deep anterior lamellar keratoplasty (DALK) using a single graft after thermokeratoplasty assisted epikeratophakia for the treatment of acute corneal hydrops.Methods: This novel surgical procedure was performed on seven eyes of seven patients between 2019 and 2020. The procedure combines a first-stage surgery of thermokeratoplasty assisted epikeratophkia with intracameral sterile air injection and a second-stage surgery of DALK using the same corneal graft for both procedures. Main outcome measures included pre- and postoperative corrected distance visual acuity (CDVA) and anterior segment optical coherence tomography (AS-OCT) parameters. Corneal transparency, epithelization, and the presence of neovascularization, were evaluated at the 1-year follow-up visit.Results: Corneal edema resolved rapidly in six of the seven cases. The mean central corneal thickness was significantly reduced from baseline to 1 day, 1 week, 1 month, and 2 months after the first-stage surgery (P < 0.0001). At a mean of 2.1 ± 0.7 months after the first-stage surgery, DALK was successfully performed in all cases. Six months later, the mean central corneal thickness was 611 ± 31 μm and the mean thickness of the recipient’s residual stroma bed was 20 ± 6 μm at the central corneal area. Mean LogMAR CDVA improved from 1.74 ± 0.34 at baseline to 0.20 ± 0.11 after DALK (P < 0.0001). No postoperative complications appeared in our case series during the 1-year observation period.Conclusion: Very good visual results were obtained with a novel technique (thermokeratoplasty assisted epikeratophakia followed by DALK using the same corneal graft) in the treatment of acute corneal hydrops.